Kevin McCaffrey

Kevin McCaffrey graduated from Rutgers University. He is a reporter with MM&M.

Most Recent Articles by Kevin McCaffrey

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, August 19

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.

Five things for pharma marketers to know: Monday, August 18

Five things for pharma marketers to know: Monday, August 18

Roche is rumored to be stalking a Chugai acquisition, Pfizer has hit its palbociclib filing deadline and Supernus scored a Fast Track designation for its experimental ADHD drug.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Kyprolis fails to wow in survival trial

Kyprolis fails to wow in survival trial

Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.

Five things for pharma marketers to know: Thursday, August 14

Five things for pharma marketers to know: Thursday, August 14

Merck insomnia aid nabs FDA approval, AZ's severe asthma drug advances to Phase III, Specialty med costs expected to comprise more and more Medicare Part D spending.

More Articles by Kevin McCaffrey

Email Newsletters